Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. Read more about Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer.
Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIβ. Read more about Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIβ.
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors. Read more about Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
Small-Molecule Allosteric Modulators of the Protein Kinase PDK1 from Structure-Based Docking. Read more about Small-Molecule Allosteric Modulators of the Protein Kinase PDK1 from Structure-Based Docking.
Hotspots in an obligate homodimeric anticancer target. Structural and functional effects of interfacial mutations in human thymidylate synthase. Read more about Hotspots in an obligate homodimeric anticancer target. Structural and functional effects of interfacial mutations in human thymidylate synthase.
Alanine mutants of the interface residues of human thymidylate synthase decode key features of the binding mode of allosteric anticancer peptides. Read more about Alanine mutants of the interface residues of human thymidylate synthase decode key features of the binding mode of allosteric anticancer peptides.
An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases. Read more about An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases.
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents. Read more about Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.
Successes and challenges in phenotype-based lead discovery for prion diseases. Read more about Successes and challenges in phenotype-based lead discovery for prion diseases.
Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumo Read more about Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumo
